Significant milestone and trading update
RUA Life Sciences released a well-received announcement on an important milestone in the commercialisation of its large bore vascular graft and its related product, the vascular patches. The release also included a trading update on group businesses. As a result of this positive development on RUA’s vascular graft product, we have updated our valuation of the product itself and RUA’s cash position at the end of September 2021.The manufacturing hiccup that had held up the US FDA’s medical device Premarket Notification (510k) submission for RUA Vascular’s large bore vascular graft earlier in June, and which was resolved before the end of the summer, has now been consigned to the past - as RUA has announced the 510k submission.
Our valuation has increased to £122.9m or 554p per share (from £116.5m or 525p per share) as a result of changing our discount rate on the vascular products to reflect the progress made, RUA’s revised cash balance at the end of H1 2022, and the deferred (from our previous forecasts) Vascular graft sales.
Equity Development enables companies to become better understood and supported by investors. Since our launch in 1996 we have consistently focused on helping our clients improve their communication and relationships with both existing and potential shareholders. Our clients have come from a wide variety of sectors and domiciles, are both private and quoted and range in size from micro-cap to $multi-billions. We offer free access to company research notes written by experienced analysts. These notes include detailed forecasts, financial models and a fair value. We host regular Private Investor Forums at which investors have the opportunity to hear company directors present, and to ask questions. These are free to attend. We broadcast live Webinars with company management that include active Q&A. We also make the recordings available online. We arrange face to face meetings between private investors and company management. We are active users of Twitter, commenting daily on company news, share price moves, Directors’ Dealings, Equity Development Research Notes & Events.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.